Regulatory Approvals

FDA Clears IND for RAG-1C saRNA candidate targeting proliferative vitreoretinopathy

By

Regulatory Approvals — FDA Clears IND for RAG-1C saRNA candidate targeting proliferative vitreoretinopathy  Ophthalmology Times Europe

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 3, 2026.

By

Related Post

Regulatory Approvals

Jeffrey Jensen, MD, reacts to FDA approval of new contraception patch, Gwyn Lo

Regulatory Approvals

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Regulatory Approvals

FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients

Financial News For All

Labor

Nurses deliver petition opposing CommonSpirit Health’s planned layoffs of frontline health care workers

Regulatory Approvals

Boeing’s smallest 737 Max wins approval after years of delay tied to crashes

Regulatory Approvals

FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients

Regulatory Approvals

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer